Clinical trial
Evaluation and Exploration of the Safety and Efficacy of Superselective Adrenal Arterial Embolization in Patients With Essential Refractory Hypertension: A Proof-of-Concept Study
NCT06568640 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Nanchang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation and Exploration of the Safety and Efficacy of Superselective Adrenal Arterial Embolization in Patients With Essential Refractory Hypertension: A Proof-of-Concept Study
- Lead sponsor
- Second Affiliated Hospital of Nanchang University
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- August 1, 2024
- Completion date
- December 31, 2027
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.